



Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.







[THEDIVIDENDPRINCE.COM](https://www.thedividendprince.com)

Price	52 week low	52 week high	Total shares outstanding	Market cap	Exchange market
151.15	140.7	168.85	2408 Millions shares	364 Billions	NYSE

The dividendprince rating*	
7.33/10	

Key Metrics

Blue Chips	Yes	✓
Brand ranking**	153	✓
Revenue (CAGR) 10 years	1.67%	✗
Net income (CAGR) 10 years	-1.05%	✗
EPS (CAGR) 10 years	0.39%	✗
Price earnings ratio	24.78	✓
Net Profit Margin TTM	16.74%	✓
Dividend payout ratio	79.71%	✗
Dividend yield	3.25%	✓
Return on equity (10y average)	24.77%	✓
Return on Tangible assets (10y average)	18.84%	✓
Return on Invested Capital TTM	14.15%	✓
Debt to equity (10y average)	0.44	✓
Debt to assets (10y average)	0.19	✓
Price to book ratio TTM	5.19	✗
Fair Value (Morningstar)	164	✓
Economic Moat (Morningstar)	Wide	✓
Long term debt rating (Moody's)	Aaa	✓
Short term debt rating (Moody's)	P-1	✓
Dividend Cut Risk Score	20.31%	✓
ESG Risk Rating (Morningstar)	20.10	✗
Financial Strength Score (Piotroski Score)	6	✓
Last Earning Call AI Sentiment Analysis	neutral	✗
Stock beats the ref. index for the last 10 years	✗	
steady revenue ?	✓	
Steady net income ?	✓	
Steady profit margin positive ?	✓	
Steady FCF ?	✓	
steady dividends and increasing ?	✓	
Nb of shares decreasing ?	✓	



[*The dividendprince rating is explained here](#)

[**Brand ranking source](#)

Disclaimer :Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this document should be seen as a recommendation to follow any investment strategy. Errors may occur.